Phase 2 Colorectal Cancer Trial, Recruiting NCT05914389 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT05914389
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old.
  • People who have been diagnosed through lab testing with a specific type of colon cancer called MSS or pMMR-type colon adenocarcinoma.
  • People whose tumor is located more than 12cm from the anus (measured by a camera scope exam), and where the tumor cannot be felt during a rectal examination.
  • People whose cancer staging from a CT scan shows a certain level of spread (T3/4 or T1-4 with lymph node involvement), without multiple tumours or spread to distant parts of the body.
  • People who are expected to live for more than one year.
  • People who have been newly diagnosed, have not yet received any cancer treatment, and have no medical reasons preventing chemotherapy.
  • People who understand the study, are willing to take part, and are able to sign a written consent form.

Who may not be able to join:

  • People who do not wish to take part in the study.
  • People who have colorectal cancer occurring in multiple separate locations.
  • People who have a history of another cancer, except for certain low-risk types such as basal cell skin cancer, a specific type of thyroid cancer, or cancers that have not spread beyond their original layer (in situ cancers).
  • People who are unable to tolerate chemotherapy, for example due to a condition affecting bone marrow function.
  • People experiencing a serious flare-up of a major organ condition (such as a lung, heart, or kidney condition) or a severe infection (such as hepatitis, pneumonia, or heart inflammation), or those rated as very high surgical risk (confirm with trial site).
  • People with a mental health condition, inability to read, or language difficulties that would prevent understanding the study.
  • People whose tumour is causing a blockage in the bowel, or where there is a high risk of blockage, bleeding, or perforation.
  • People who have nerve damage affecting sensation in their hands or feet that would prevent them from receiving a specific chemotherapy drug (oxaliplatin).
  • People who are pregnant or breastfeeding.
  • People who are unable to have a contrast-enhanced CT scan, or who have another condition requiring ongoing steroid (glucocorticoid) medication.
  • People who have used steroid (glucocorticoid) medication continuously for more than 3 days in the month before signing the consent form.
  • People whose tumour position, as seen on a CT or MRI scan, falls below a specific anatomical line in the pelvis (confirm with trial site for details).
  • People who the trial researchers consider unsuitable for the study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jun Li, MD, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +86 13777878061

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
1 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

TRG0/1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov